fbpx
Pipeline

Other Programs

Pioneering the Immunotherapy Landscape

At Atara Biotherapeutics, we are exploring the utility of our targeted antigen recognition technology in EBV and other virally driven diseases. Through our strategic collaboration with QIMR Berghofer, we have developed additional product candidates that target a number of diseases, including refractory cytomegalovirus (CMV) infection and disease post hematopoietic cell transplantation (HCT) or solid organ transplantation (SOT), hematologic malignancies, JCV PML and BKVAN, as well as HPV associated cancers. As we move forward, we will continue to improve upon our robust pipeline of high potential candidates and thus uphold our position as a leading allogeneic T-cell immunotherapy company.

Pipeline

Indication/Program Preclinical Phase 1 Phase 2 Phase 3
ATA230: Refractory CMV Infection and Disease Post HCT/SOT

ATA230: Refractory CMV Infection and Disease Post HCT/SOT

ATA520: Hematologic malignancies
ATA621: JCV PML and BKVAN
ATA368: HPV associated cancers
Indication/Program Phase
ATA230: Refractory CMV Infection and Disease Post HCT/SOT Phase 2

ATA230: Refractory CMV Infection and Disease Post HCT/SOT

ATA520: Hematologic malignancies Phase 1
ATA621: JCV PML and BKVAN Preclinical
ATA368: HPV associated cancers Preclinical

ATA230

ATA230 is an off-the-shelf CMV-specific T-cell immunotherapy targeting antigens expressed by cytomegalovirus (CMV). ATA230 has been investigated in one Phase 1 and two Phase 2 clinical studies for refractory CMV infection that occurs in immunocompromised patients who have received an HCT or a SOT.

In October 2017, ATA230 was granted Rare Pediatric Disease Designation by the FDA for the treatment of congenital CMV infection, and in September 2017, ATA230 received orphan drug designation in the U.S. for the treatment of CMV viremia and disease in immunocompromised patients.

In October 2016, The European Medicines Agency (EMA) also issued a positive orphan drug designation opinion for ATA230 for the treatment of CMV infection in patients with impaired cell-mediated immunity.

About Cytomegalovirus

Cytomegalovirus (CMV) is a common virus that infects people of all ages. Once inside a person’s body, the virus remains inside for life and can potentially be reactivated. In patients with weakened immune systems, such as recent bone marrow and solid organ transplant recipients, newborns with immature immune systems, and those with human immunodeficiency virus (HIV), CMV can cause potentially life-threatening diseases or may result in blindness, brain damage, and deafness.

While small molecule antiviral drugs are approved to treat and prevent CMV infection, there remains a high unmet need due to viral resistance, modest neurodevelopmental activity and adverse effects, such as toxicity and reduction in white blood cell count impairing the ability to fight other infections, with these agents.

ATA520

ATA520 is an allogeneic T-cell immunotherapy targeting cancers expressing Wilms Tumor 1 (WT1) antigens. WT1 is an intracellular protein that is overexpressed in a number of cancers, including multiple myeloma (MM) and non-small cell lung, breast, pancreatic, ovarian, and colorectal cancers.

Memorial Sloan Kettering Cancer Center (MSK) has two Phase 1 clinical trials evaluating ATA520. The first trial was a dose escalation trial of ATA520 for residual or relapsed leukemia after HCT. The second ATA520 Phase 1 study was for patients following T cell depleted HCT with relapsed or refractory MM, including plasma cell leukemia (PCL).

About Plasma Cell Leukemia

Plasma cell leukemia (PCL) is a rare and aggressive form of multiple myeloma (MM) characterized by high levels of abnormal plasma cells circulating in the peripheral (circulating) blood. PCL can either present itself as a progression of previously diagnosed multiple myeloma or as the initial manifestation of disease.

There is a high unmet medical need in patients with PCL, who are estimated to have a median survival of seven to 11 months. When PCL occurs in the context of refractory or relapsing MM, survival is estimated to be two to seven months.

ATA621 Benefits

Indication
JCV PML and BKVAN
Target
BK/JCV
Technologies
Selective viral antigen targeting
Collaborator
QIMR Berghofer

ATA621 Benefits

Indication
HPV associated cancers
Target
HPV
Technologies
Selective viral antigen targeting
Collaborator
QIMR Berghofer